These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

755 related articles for article (PubMed ID: 20831289)

  • 21. Comparative effectiveness research: the view from a pharmaceutical company.
    Berger ML; Grainger D
    Pharmacoeconomics; 2010; 28(10):915-22. PubMed ID: 20831299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
    Wong CKH; Wu O; Cheung BMY
    Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
    Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
    Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient advocate perspectives on involvement in HTA: an international snapshot.
    Scott AM; Wale JL;
    Res Involv Engagem; 2017; 3():2. PubMed ID: 29062527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Review of Current Approaches to Evaluating and Reimbursing New Medicines in a Subset of OECD Countries.
    Zozaya N; Villaseca J; Fernández I; Abdalla F; Cadenas-Noreña B; Calleja MÁ; Gómez-Pajuelo P; Mestre-Ferrándiz J; Oliva-Moreno J; Trillo JL; Hidalgo-Vega Á
    Appl Health Econ Health Policy; 2024 May; 22(3):297-313. PubMed ID: 38214848
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health Technology Assessment for Molecular Diagnostics: Practices, Challenges, and Recommendations from the Medical Devices and Diagnostics Special Interest Group.
    Garfield S; Polisena J; S Spinner D; Postulka A; Y Lu C; Tiwana SK; Faulkner E; Poulios N; Zah V; Longacre M
    Value Health; 2016; 19(5):577-87. PubMed ID: 27565275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranking the Criteria Used in the Appraisal of Drugs for Reimbursement: A Stated Preferences Elicitation With Health Technology Assessment Stakeholders Across Jurisdictional Contexts.
    Wranik WD; Jakubczyk M; Drachal K
    Value Health; 2020 Apr; 23(4):471-480. PubMed ID: 32327164
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PAYER PERSPECTIVES ON FUTURE ACCEPTABILITY OF COMPARATIVE EFFECTIVENESS AND RELATIVE EFFECTIVENESS RESEARCH.
    Moloney R; Mohr P; Hawe E; Shah K; Garau M; Towse A
    Int J Technol Assess Health Care; 2015 Jan; 31(1-2):90-8. PubMed ID: 26168804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Harmonization of evidence requirements for health technology assessment in reimbursement decision making.
    Hutton J; Trueman P; Facey K
    Int J Technol Assess Health Care; 2008; 24(4):511-7. PubMed ID: 18828948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patient advocacy group involvement in health technology assessments: an observational study.
    Single A; Cabrera A; Fifer S; Tsai J; Paik JY; Hope P
    Res Involv Engagem; 2021 Nov; 7(1):83. PubMed ID: 34823610
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.
    Allen D; Gillen E; Rixson L
    JBI Libr Syst Rev; 2009; 7(3):80-129. PubMed ID: 27820426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis.
    Jenei K; Gentilini A; Haslam A; Prasad V
    Lancet Oncol; 2024 Aug; 25(8):979-988. PubMed ID: 39004098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Appraisals by Health Technology Assessment Agencies of Economic Evaluations Submitted as Part of Reimbursement Dossiers for Oncology Treatments: Evidence from Canada, the UK, and Australia.
    Ball G; Levine MAH; Thabane L; Tarride JE
    Curr Oncol; 2022 Oct; 29(10):7624-7636. PubMed ID: 36290879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Do different clinical evidence bases lead to discordant health-technology assessment decisions? An in-depth case series across three jurisdictions.
    Spinner DS; Birt J; Walter JW; Bowman L; Mauskopf J; Drummond MF; Copley-Merriman C
    Clinicoecon Outcomes Res; 2013; 5():69-85. PubMed ID: 23403392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Revealed and Stated Preferences of Decision Makers for Priority Setting in Health Technology Assessment: A Systematic Review.
    Ghijben P; Gu Y; Lancsar E; Zavarsek S
    Pharmacoeconomics; 2018 Mar; 36(3):323-340. PubMed ID: 29124632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries.
    Kleijnen S; Lipska I; Leonardo Alves T; Meijboom K; Elsada A; Vervölgyi V; d'Andon A; Timoney A; Leufkens HG; De Boer A; Goettsch WG
    Ann Oncol; 2016 Sep; 27(9):1768-75. PubMed ID: 27329251
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Value of New: Consideration of Product Novelty in Health Technology Assessments of Pharmaceuticals.
    Synnott PG; Voehler D; Enright DE; Kowal S; Ollendorf DA
    Appl Health Econ Health Policy; 2023 Mar; 21(2):305-314. PubMed ID: 36529826
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surrogate Endpoints in Health Technology Assessment: An International Review of Methodological Guidelines.
    Grigore B; Ciani O; Dams F; Federici C; de Groot S; Möllenkamp M; Rabbe S; Shatrov K; Zemplenyi A; Taylor RS
    Pharmacoeconomics; 2020 Oct; 38(10):1055-1070. PubMed ID: 32572825
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Can CER be an effective tool for change in the development and assessment of new drugs and technologies?
    Brixner DI; Watkins JB
    J Manag Care Pharm; 2012 Jun; 18(5 Supp A):S06-11. PubMed ID: 22663293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.